French biotech company Alaxia has announced a collaboration with the Department of Molecular Medicine (DMM) at the University of Padua for in vitro testing of its ALX-009 hypothiocyanite / lactoferrin inhalation solution against SARS-CoV-2 as a possible treatment for COVID-19. The company has been developing ALX-009 as an inhaled antimicrobial for the treatment of … [Read more...] about Alaxia partners with University of Padua to evaluate ALX-009 inhalation solution against SARS-CoV-2
News
Ampio announces planned Phase 1 trial of inhaled Ampion in COVID-19 patients
Ampio Pharmaceuticals said that the FDA has cleared its IND for clinical trials of an inhaled formulation of its Ampion anti-inflammatory biologic in patients with COVID-19. The company had announced its plans to develop Ampion for the treatment of COVID-19 in March 2020. According to Ampio, preclinical toxicology studies demonstrated that Ampion would be safe for … [Read more...] about Ampio announces planned Phase 1 trial of inhaled Ampion in COVID-19 patients
Teva launches AirDuo Digihaler and ArmonAir Digihaler in the US
Teva Respiratory has launched its AirDuo Digihaler fluticasone propionate / salmeterol and ArmonAir Digihaler fluticasone propionate DPIs in the US, the company said. The company announced the launch of its ProAir Digihaler albuterol sulfate DPI in July 2020. AirDuo Digihaler was approved by the FDA for the treatment of asthma in July 2019, and the agency approved … [Read more...] about Teva launches AirDuo Digihaler and ArmonAir Digihaler in the US
Perrigo announces US recall of albuterol MDIs
Perrigo said that the company stopped production and distribution of its albuterol sulfate metered dose inhalers in the US and has issued a recall of the MDIs "out of an abundance of caution as a result of complaints that some units may not dispense due to clogging." The company noted that the inhalers are manufactured by Catalent Pharma Solutions and said that there … [Read more...] about Perrigo announces US recall of albuterol MDIs
TFF to advance its dry powder voriconazole to Phase 2 after successful Phase 1 trial
TFF Pharmaceuticals has announced that it will advance its voriconazole inhalation powder into Phase 2 development for the treatment of invasive pulmonary aspergillosis following completion of a Phase 1 trial that demonstrated plasma levels that should be sufficient for effective treatment. Topline safety results from the trial were reported in June 2020, and in July, … [Read more...] about TFF to advance its dry powder voriconazole to Phase 2 after successful Phase 1 trial
Starpharma says tests show its astodrimer sodium nasal spray formulation effectively inactivates SARS-CoV-2
Starpharma has announced that testing of its SPL7013 astodrimer sodium intranasal formulation at the Scripps Research Institute demonstrated that the formulation inactivated nearly 100% of SARS-CoV-2 with low cellular toxicity. The company already markets several astodrimer sodium products under the VivaGel brand in a number of countries, including a VivaGel condom … [Read more...] about Starpharma says tests show its astodrimer sodium nasal spray formulation effectively inactivates SARS-CoV-2
Seelos Therapeutics gets Japanese patent for intranasal racemic ketamine
According to Seelos Therapeutics, the Japanese Patent Office has issued Japanese patent number 6722453, titled "Anxiolytic Composition, Formulation and Method of Use," covering the company's SLS-002 intranasal racemic ketamine formulation for treatment of anxiety due to phobias. In addition, the company said that it received a notice of allowance for Japanese patent … [Read more...] about Seelos Therapeutics gets Japanese patent for intranasal racemic ketamine
Vectura to work on Monash University oxytocin DPI
Inhaled drug CDMO Vectura has entered into an agreement with the Monash University Institute of Pharmaceutical Sciences (MIPS) for early development of an oxytocin DPI for the prevention of postpartum hemorrhage, the company said. Vectura will develop a single use inhaler for Phase 1 clinical trials on a fee-for-service basis; a commercial manufacturer would be … [Read more...] about Vectura to work on Monash University oxytocin DPI
Phase 3 trial of Satsuma’s DHE nasal powder for migraine fails to meet primary endpoints
Satsuma Pharmaceuticals said that the Phase 3 EMERGE trial of its STS101 dihydroergotamine nasal powder for the treatment of migraine failed to demonstrate statistically significant improvement in either pain relief or the patient's most bothersome symptom compared to placebo for either of the doses tested at two hours post dosing. The company had announced the … [Read more...] about Phase 3 trial of Satsuma’s DHE nasal powder for migraine fails to meet primary endpoints
Savara announces resignations of CEO and President
Inhaled drug developer Savara has announced the departures of its co-founders, CEO Rob Neville and President and Chief Business Officer Taneli Jouhikainen, who have resigned "to pursue other opportunities," according to the company. Matthew Pauls, who has been a member of the company's board of directors since Mast's 2017 merger with Savara, will step in as interim … [Read more...] about Savara announces resignations of CEO and President